Gerold Bepler

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer
    Gerold Bepler
    Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 20:1353-60. 2002
  2. ncbi Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance
    Gerold Bepler
    Thoracic Oncology Program, Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Lung Cancer 47:183-92. 2005
  3. ncbi Using translational research to tailor the use of chemotherapy in the treatment of NSCLC
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Lung Cancer 50:S13-4. 2005
  4. ncbi RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 22:1878-85. 2004
  5. ncbi A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Cancer Control 10:306-14. 2003
  6. ncbi RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 24:4731-7. 2006
  7. pmc Pharmacogenomics: a reality or still a promise?
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Lung Cancer 54:S3-7. 2006
  8. pmc Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer
    Gerold Bepler
    Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 3:1112-8. 2008
  9. ncbi Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
    George Simon
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 25:2741-6. 2007
  10. pmc Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008

Collaborators

Detail Information

Publications78

  1. ncbi Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer
    Gerold Bepler
    Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 20:1353-60. 2002
    ..NSCLC frequently manifests loss of heterozygosity (LOH) at chromosome segment 11p15.5. Whether LOH at 11p15.5 is an independent prognostic variable has yet to be determined...
  2. ncbi Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance
    Gerold Bepler
    Thoracic Oncology Program, Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Lung Cancer 47:183-92. 2005
    ..We conclude that clinical studies using RR37 and RR524 for decisions on chemotherapy are premature and that further functional studies on the RRM1 promoter are required to fully elucidate factors controlling RRM1 expression...
  3. ncbi Using translational research to tailor the use of chemotherapy in the treatment of NSCLC
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Lung Cancer 50:S13-4. 2005
    ..The discovery of prognostic molecular markers, such as the putative suppressor gene (RRM1), represents a novel and potential parameter to help guide clinical treatment decisions...
  4. ncbi RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 22:1878-85. 2004
    ..It is located in a region of loss of heterozygosity in non-small-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC...
  5. ncbi A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Cancer Control 10:306-14. 2003
    ..Computed tomography (CT) screening of the chest has shown promise for early detection of lung cancer, but evidence for a reduction in lung cancer mortality by CT screening is not available...
  6. ncbi RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, MRC 4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 24:4731-7. 2006
    ..However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed...
  7. pmc Pharmacogenomics: a reality or still a promise?
    Gerold Bepler
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Lung Cancer 54:S3-7. 2006
    ....
  8. pmc Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer
    Gerold Bepler
    Program and Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 3:1112-8. 2008
    ..The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response...
  9. ncbi Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
    George Simon
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 25:2741-6. 2007
    ..We hypothesized that selection of double-agent chemotherapy based on tumoral RRM1 and ERCC1 expression would be feasible and beneficial for patients with advanced NSCLC...
  10. pmc Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
    Zhong Zheng
    Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Cancer 112:2765-73. 2008
    ..We hypothesized that intratumoral TS expression would be prognostic of outcome in stage I NSCLC...
  11. pmc Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    Eric B Haura
    Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 28:1387-94. 2010
    ....
  12. doi Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
    Tawee Tanvetyanon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Clin Oncol 26:4610-6. 2008
    ....
  13. pmc Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer
    Gerold Bepler
    Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Thorac Oncol 6:553-8. 2011
    ..A reduction in both local and distant recurrence is needed to improve patients' outcome. Performing molecular studies on serially collected tumor specimens may result in a better selection of therapeutic options...
  14. pmc Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:484-90. 2010
    ..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC...
  15. doi Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
    Future Oncol 4:51-9. 2008
    ....
  16. ncbi Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    Thoracic Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Oncology 68:382-90. 2005
    ..Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival...
  17. pmc ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling
    Smitha Pillai
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Mol Cell Biol 31:3052-67. 2011
    ....
  18. ncbi EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer
    Bernadette Ferraro
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, MRC3 E, Room 3056, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 23:1921-6. 2005
    ..For these reasons, we hypothesized that reduced levels of EGR1 would correlate with inferior outcome in patients with NSCLC...
  19. ncbi Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
    Eric B Haura
    Thoracic Oncology Program and Biostatistics Core, The H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Clin Cancer Res 11:8288-94. 2005
    ..We evaluated Stat3 activation in early stage non-small cell lung cancers (NSCLC) and how this relates to upstream epidermal growth factor receptor (EGFR) activation, tumor apoptosis, and prognosis...
  20. doi Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
    ..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)...
  21. ncbi Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720
    Gerold Bepler
    Program and Divison of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    Clin Lung Cancer 8:509-11. 2007
  22. doi Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers
    Tawee Tanvetyanon
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Thorac Oncol 5:1018-24. 2010
    ..For those undergoing surgery, limited information exists on the relationship between tumor size and survival...
  23. ncbi DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer
    Zhong Zheng
    From the Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    N Engl J Med 356:800-8. 2007
    ..RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis, tumor progression, and the response of non-small-cell lung cancer to treatment...
  24. pmc Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Int J Biochem Cell Biol 39:1318-28. 2007
    ..This approach is currently being validated in a prospective phase III trial. In the future, assessment of NER function may play a central role in NSCLC treatment decision making...
  25. pmc Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
    ..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target...
  26. doi Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
    Alberto Chiappori
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Thorac Oncol 5:369-75. 2010
    ..We examined the efficacy of enzastaurin plus pemetrexed as second-line therapy in patients with advanced (stage IIIA/B or IV) non-small cell lung cancer in a double-blinded, randomized, phase II study...
  27. doi Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Alberto A Chiappori
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 14:1464-9. 2008
    ..This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to determine the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin...
  28. ncbi A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer
    Tawee Tanvetyanon
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Thorac Oncol 2:1091-7. 2007
    ..We evaluated available literatures to summarize the state of current knowledge and provide suggestions for future studies...
  29. ncbi Neoadjuvant chemotherapy for resectable non-small-cell lung cancer
    Jhanelle Gray
    University of South Florida, Tampa, FL, USA
    Oncology (Williston Park) 23:879-86. 2009
    ..To clarify these issues, well-structured phase III trials comparing adjuvant to neoadjuvant chemotherapy are needed...
  30. ncbi Molecular analysis-based treatment strategies for non-small cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:130-9. 2008
    ..Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions...
  31. pmc Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers
    Jhanelle E Gray
    Moffitt Cancer Center, Tampa, FL, USA
    Cancer 119:1023-32. 2013
    ..The authors of this report evaluated enzastaurin, a selective protein kinase C-β (PKC-β) inhibitor with antiproliferative and proapoptotic properties, in former smokers...
  32. ncbi Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer
    Nithya Ramnath
    H Lee Moffitt Cancer Center and Research Institute, Thoracic Oncology Program, Tampa, FL 33612, USA
    Chest 128:3467-74. 2005
    ..The primary clinical end point was radiographic disease response rate, and the secondary end points were pathologic response rate, treatment-related toxicity, surgical resectability and outcome, and overall and disease-free survival...
  33. doi Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis
    Tawee Tanvetyanon
    Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
    J Clin Oncol 26:1142-7. 2008
    ..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis...
  34. ncbi ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Ste 3170, Tampa FL 33612, USA
    Chest 127:978-83. 2005
    ..We therefore evaluated the effect of intratumoral ERCC1 expression on survival in non-small cell lung cancer (NSCLC) patients who underwent surgical resection for cure...
  35. ncbi Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung
    Luke T Nordquist
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Suite 3170, Tampa, FL 33612, USA
    Chest 126:347-51. 2004
    ..Lee Moffitt Cancer Center, and looked for demographic and survival differences in the two groups...
  36. doi Physician referral for fertility preservation in oncology patients: a national study of practice behaviors
    Gwendolyn P Quinn
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 27:5952-7. 2009
    ..This study examined the referral practices of oncologists in the United States...
  37. ncbi Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center Research Institute, Tampa, FL 33612, USA
    Cancer Control 10:388-95. 2003
    ..We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor...
  38. ncbi Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer
    Zhong Zheng
    Thoracic Oncology Program, The H Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Chest 128:308-16. 2005
    ..We also hypothesized that EGFR activity may be prognostic for early-stage NSCLC...
  39. pmc A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors
    Jhanelle E Gray
    Authors Affiliations Departments of Thoracic Oncology, Head and Neck Oncology, and Cutaneous Oncology Chemical Biology and Molecular Medicine Program Clinical Pharmacology Core Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida and Karmanos Cancer Institute, Detroit, Michigan
    Clin Cancer Res 20:1644-55. 2014
    ..We evaluated this combination in patients with advanced NSCLC and head and neck cancer...
  40. ncbi Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer
    Jun Yang
    Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Lung Cancer 46:29-42. 2004
    ..The present study used immunohistochemistry to evaluate the prognostic effect of gelsolin expression in 155 patients with resectable NSCLC...
  41. doi Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands
    Tawee Tanvetyanon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa FL 33612, USA
    Cancer 113:150-7. 2008
    ..In the current study, the authors investigated the risk of lung cancer associated with beta-carotene in smokers or former smokers and surveyed the beta-carotene content in national brand multivitamins...
  42. ncbi Molecular predictors of chemotherapy response in non-small-cell lung cancer
    Jhanelle Gray
    H Lee Moffitt Cancer Center and Research Institute, Division of Thoracic Oncology, Tampa, Florida 33612, USA
    Expert Rev Anticancer Ther 7:545-9. 2007
    ..Recently, how these genes affect lung cancer therapy has been explored in the clinical setting with the goal of finding customized treatment algorithms to optimize efficacy, improve outcomes and minimize toxicity...
  43. ncbi Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
    Scott J Antonia
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:878-87. 2006
    ....
  44. ncbi Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies
    Eric B Haura
    Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 6:113-22. 2004
    ....
  45. pmc Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET
    Marilyn M Bui
    Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612 9497, USA
    Fetal Pediatr Pathol 29:385-92. 2010
    ..High TS1 expression, not RRM1 and ERCC1, was associated with long overall survival (p value = 0.057). Thus in-situ TS1 protein expression in Ewing/PNET is a prognostic marker...
  46. ncbi RRM1-induced metastasis suppression through PTEN-regulated pathways
    Ashish Gautam
    Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, New York, USA
    Oncogene 22:2135-42. 2003
    ..Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression...
  47. ncbi Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions
    Teresita Munoz-Antonia
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Cancer 110:1527-31. 2007
    ..The authors previously observed that, in head and neck squamous cell carcinoma, the expression of the TGFbeta type II receptor (TbetaR-II) decreases as tumors become less differentiated and more biologically aggressive...
  48. doi Lung cancer patients' decisions about clinical trials and the theory of planned behavior
    Gwendolyn P Quinn
    Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
    J Cancer Educ 26:641-8. 2011
    ..Results indicate that the theory of planned behavior may be a useful tool to examine psychosocial needs in relation to behavioral intention of clinical trial participation...
  49. ncbi Obtaining DNA from a geographically dispersed cohort of current and former smokers: use of mail-based mouthwash collection and monetary incentives
    Joseph E Bauer
    Department of Health Behavior, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Nicotine Tob Res 6:439-46. 2004
    ..This pilot study showed that this requirement could pose some challenges in population-based research...
  50. pmc Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting
    Vani Nath Simmons
    Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, USA
    Patient Educ Couns 77:398-403. 2009
    ..To fill a gap in research by examining cancer patient-provider communication regarding tobacco use and patients' perspectives regarding their experiences with smoking cessation and relapse...
  51. ncbi Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase
    Ashish Gautam
    Division and Program of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 66:6497-502. 2006
    ..We conclude that the regulatory subunit of ribonucleotide reductase has tumor suppressor activity that is mediated through efficient DNA damage repair...
  52. ncbi Malignant pleural mesothelioma: a comprehensive review
    Roohi Ismail-Khan
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:255-63. 2006
    ..The incidence of malignant mesothelioma continues to increase, but the disease remains difficult to detect early and treat effectively...
  53. ncbi The guinea pig syndrome: improving clinical trial participation among thoracic patients
    Gwendolyn P Quinn
    Division and Program of Thoracic Oncology, H L Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    J Thorac Oncol 2:191-6. 2007
    ....
  54. ncbi Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer
    Dong Feng Tan
    Lung Cancer Program, Roswell Park Cancer Institute, State University of New York, Buffalo, New York 14263, USA
    Anticancer Res 23:1665-72. 2003
    ..This information may also potentially serve as a tool for clinical decision-making when selecting patients for adjuvant treatments of NSCLC...
  55. pmc Proteomic contributions to personalized cancer care
    John M Koomen
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Mol Cell Proteomics 7:1780-94. 2008
    ....
  56. pmc Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
    Arch Intern Med 168:632-42. 2008
    ..We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions...
  57. ncbi Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
    ..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability...
  58. ncbi Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition)
    Jhanelle Gray
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Room 4046, Tampa, FL 33612, USA
    Chest 132:56S-68S. 2007
    ..Chemoprevention is the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention...
  59. ncbi Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer
    Ibrahim S Aljada
    Roswell Park Cancer Institute, State University of New York, Buffalo, Elm and Carlton Sts, Buffalo, NY 14263, USA
    J Clin Oncol 22:3218-29. 2004
    ....
  60. pmc A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation
    Donghwa Kim
    Departments of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Biol Chem 285:8383-94. 2010
    ....
  61. pmc Regular aspirin use and lung cancer risk
    Kirsten B Moysich
    Roswell Park Cancer Institute, Buffalo, NY, USA
    BMC Cancer 2:31. 2002
    ....
  62. pmc Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines
    Jun Zhou
    Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    J Nucleic Acids 2010:597098. 2010
    ..The impact of p53 mutations in patients treated with gemcitabine should be studied in prospective clinical trials to develop a model with improved precision of predicting drug efficacy...
  63. ncbi Lung cancer. Practice organization
    W Michael Alberts
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Chest 123:332S-337S. 2003
    ..Treatment recommendations should be based on locally agreed-on adaptations of clinical practice guidelines. Provisions for ongoing care should be apparent to all concerned..
  64. ncbi Southern Blotting of genomic DNA from lung and its tumors. Application to analysis of allele loss on chromosome 11p15.5
    Diana M Pitterle
    Department of Surgery, University of Wisconsin Madison Medical School, Madison, WI, USA
    Methods Mol Med 75:263-77. 2003
  65. ncbi Non-small cell lung cancer
    David S Ettinger
    J Natl Compr Canc Netw 6:228-69. 2008
  66. ncbi Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer
    Brandon A Howard
    Department of Radiology, Duke University, Durham, NC, USA
    Lung Cancer 46:313-23. 2004
    ..While both proteins considered in this study were overexpressed in the vast majority of NSCLCs, they were not found to be of prognostic significance...
  67. ncbi Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
    Rafael Rosell
    Department of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Oncogene 22:3548-53. 2003
    ..The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival...
  68. doi Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Yun Oh
    Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:1135-41. 2008
    ..This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC...
  69. ncbi Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
    Rafael Rosell
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
    Clin Cancer Res 10:1318-25. 2004
    ..Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity...
  70. ncbi Targeted therapy in combination with gemcitabine in non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Semin Oncol 30:19-25. 2003
    ..Preliminary findings that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival and highlight the possibilities of individually tailored chemotherapy...
  71. ncbi Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia
    Scott N Freeman
    J Natl Cancer Inst 97:1088-9; author reply 1093-5. 2005
  72. ncbi Lung cancer: provoking new concepts, generating novel ideas, and rekindling enthusiasm
    Gerold Bepler
    Cancer Control 10:275-6. 2003
  73. ncbi Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
    Jhanelle Gray
    Department of Thoracic Oncology, Yale New Haven Medical Center, New Haven, Connecticut, USA
    J Thorac Oncol 2:571-3. 2007
    ..In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab...
  74. doi The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes
    Suzanne C O'Neill
    Social and Behavioral Research Branch, NHGRI NIH, Bethesda, Maryland 20892, USA
    Genet Med 10:121-30. 2008
    ..Outcomes include proportion who logged on to the study website to consider testing, made informed decisions to log on and to be tested...
  75. ncbi Statins and lung cancer risk
    Jhanelle Gray
    Chest 131:1274-5. 2007
  76. ncbi Reported cessation advice given to African Americans by health care providers in a community health clinic
    Kathryn I Pollak
    Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27710 2949, USA
    J Community Health 27:381-93. 2002
    ..Providers may need additional training and prompting to counsel young healthy smokers about the importance of cessation...
  77. ncbi Non-small cell lung cancer clinical practice guidelines in oncology
    David S Ettinger
    J Natl Compr Canc Netw 4:548-82. 2006
  78. ncbi Interpretation of genetic risk feedback among African American smokers with low socioeconomic status
    Isaac M Lipkus
    Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27701, USA
    Health Psychol 23:178-88. 2004
    ..The authors suggest additional research is needed to develop more effective strategies for communicating genetic risk feedback to motivate smoking cessation...